U.S. License Holder:
Date of License:
ILARIS (canakinumab) is an interleukin-1 beta blocker indicated for the treatment of:
Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including:
Familial Cold Autoinflammatory Syndrome (FCAS);
Muckle-Wells Syndrome (MWS);
Active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.